A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Benralizumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms SOLANA
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Oct 2017 Planned End Date changed from 3 May 2018 to 20 Aug 2018.
    • 12 Oct 2017 Planned primary completion date changed from 3 May 2018 to 20 Aug 2018.
    • 19 Dec 2016 Planned End Date changed from 1 Mar 2018 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top